News
Viral scandals have hit two actresses, a Harvard graduate and a doctor from a top Beijing hospital in recent months.
Abbott Laboratories(NYSE:ABT) reported its second-quarter 2025 results on July 17, 2025, posting 7.5% organic sales growth (excluding COVID testing), 12% medical device growth, and adjusted EPS of $1.
The Iowa Republican spoke in support of the bill passed early Thursday making cuts to foreign aid and public broadcasting.
Discover Abbott Laboratories' Q2 2025 highlights: resilience drives high single-digit growth, double-digit EPS, and pipeline innovations.
Medical Devices achieved strong double-digit growth, while the Diagnostics segment in China saw ongoing pressure. These 10 stocks could mint the next wave of millionaires › Abbott Laboratories ...
Abbott warned on Thursday it expects more than $1 billion in financial headwinds this year from a sharp decline in COVID-19 testing demand, new U.S. tariffs, and the government's foreign aid freeze.
The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.
Last year, 1.14 million tourists visited Nepal, and the government has projected up to 10% increase in tourist arrivals this ...
As part of the arrangement, Baidu will introduce thousands of its Apollo Go autonomous vehicles on Uber’s platform in areas ...
Australian Prime Minister Anthony Albanese visited a panda breeding facility in the final stages of an extended state visit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results